Sign up Australia
Proactive Investors - Run By Investors For Investors

Rosy outlook, newly issued patents boost VistaGen Therapeutics’ antidepressant AV-101, says Oppenheimer

The analysts expect the San Francisco biotech’s new generation of antidepressant to be launched by 2023
A woman clutching her head
Shares of the biotech were 3.3% higher on Wednesday

Analysts at Oppenheimer said Friday that a “rosy outlook” and newly issued patents elevated VistaGen Therapeutics Inc.’s (NASDAQ:VTGN) new generation antidepressant AV-101.

The analysts said that the US Patent and Trademark Office has issued two key patents for VistaGen's lead asset AV-101.

“Management estimates that these patents would not expire until at least 2034 and represent a fundamental milestone,” wrote Oppenheimer analysts Jay Olson and Silvan Tuerkcan in a note to clients.

“We believe VistaGen’s unique antidepressant (AV-101) may offer ketamine-like efficacy without the side effects or inconvenience, and recently initiated coverage with a US$6 price target,” they added.

READ: VistaGen Therapeutics rockets after Oppenheimer initiates coverage with Outperform rating, US$6 price target

The analysts said VistaGen currently has a pair of Phase 2 trials running to demonstrate the “efficacy and safety of AV-101 in patients with depression and an inadequate response to at least one prior treatment.”

Data from the first, smaller trial, with 25 participants, is expected to come in by the end of 2018. The second, larger trial with 180 subjects isn’t expected to throw up results until mid-2019.

Investment thesis

The Oppenheimer note indicated that if the Phase 2 trials are successful, VistaGen could begin pivotal trials by early-2020, with potential NDA filing in 2022. The antidepressant would then be expected to launch in the United States in 2023.

“We estimate 4 million major depressive disorder (MDD) patients in the US are candidates for AV-101,” wrote the analysts. “We forecast a peak 5% market share and $7,000 annual net price, implying peak sales of $1.5bn with 25% probability of success and $373 million risk-adjusted sales in 2030.”

The analysts viewed VistaGen as “underappreciated and undervalued,” with a novel, “potentially best-in-class, rapid acting” oral antidepressant.

“We assume that AV-101 has a product life cycle lasting until at least 2030,” the analysts said in their base case assumption.

Shares of the biotech were trading 3.3% higher at US$1.46 on Wednesday.

View full VTGN profile View Profile

VistaGen Therapeutics Inc Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use